A study of Pulmonary Disease revealed that Mepolizumab reduces shortness of breath and chest infections by up to 20% compared to current treatments.
The study was conducted by researchers from the Department of Lung, sensitive, intensive care and sleep medicine, from the University of Pittsburgh in the United States, and its results were published in the New England Journal of Medicine and the British Daily Mail wrote about it.
Mipolisome reduces the need for patients with lung diseases to enter the hospital.
Mipolisome is a drug consisting of a single-astuous antibiotic body for intercinkine-5 and results in a decrease in the allergic symptoms of asthma. Warlet antibodies are human -made proteins that work like antibodies in the immune system.
Chronic pulmonary blockage
Chronic obstructive pulmonary disease is a common pulmonary disease that causes air flow and breathing problems. It is sometimes called puffy lung or chronic bronchitis, according to the World Health Organization website.
Chronic obstructive pulmonary disease in people with it can damage or block the lungs. Symptoms include coughing, sometimes accompanied by sputum, difficulty breathing, whistling and fatigue.
Smoking and air pollution are the two most common causes of chronic obstructive pulmonary disease. People with chronic obstructive pulmonary disease are more likely to develop other health problems.
Chronic obstructive pulmonary disease cannot be recovered, but symptoms can improve if one avoids smoking and exposure to air pollution, and gets the necessary vaccines to prevent infection. It can also be treated with medications, oxygen and pulmonary rehabilitation.
Inhalation devices
There are many treatments available for chronic obstructive pulmonary disease. The most important treatments are inhaled drugs that open the airways and reduce their swelling. The expanded inhalation devices of the bronchi are the most important drugs for the treatment of chronic obstructive pulmonary disease, and to help the airways to relax to keep them open.
The experiment, which was conducted on those with chronic obstructive pulmonary disease, was found that the medolisumab reduces shortness of breath and chest infections by up to 20% compared to the current treatments.
In the case of chronic bronchitis patients (Chronic Bronchitis), a form of disease in which the lungs are filled with mucus, mabulizumab reduced the serious symptoms of up to a third. It also decreased throughout the year of patients ’entry to the hospital by 35%.